The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Evaluating the state of the science for adeno-associated virus integration: An integrated perspective
Open accessAbstract
On August 18, 2021, the American Society of Gene and Cell Therapy (ASGCT) hosted a virtual roundtable on adeno-associated virus (AAV) integration, featuring leading experts in preclinical and clinical AAV gene therapy, to further contextualize and understand this phenomenon. Recombinant AAV (rAAV) vectors are used to develop therapies for many conditions given their ability to transduce multiple cell types, resulting in long-term expression of transgenes. Although most rAAV DNA typically remains episomal, some rAAV DNA becomes integrated into genomic DNA at a low frequency, and rAAV insertional mutagenesis has been shown to lead to tumorigenesis in neonatal mice. Currently, the risk of rAAV-mediated oncogenesis in humans is theoretical because no confirmed genotoxic events have been reported to date. However, because insertional mutagenesis has been reported in a small number of murine studies, there is a need to characterize this genotoxicity to inform research, regulatory needs, and patient care. The purpose of this white paper is to review the evidence of rAAV-related host genome integration in animal models and possible risks of insertional mutagenesis in patients. In addition, technical considerations, regulatory guidance, and bioethics are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Self-citationA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Self-citationEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 4×
“AAV serotypes differ based on the composition of the capsid protein, and as a result target different tissues, known as tropism.(7,10) For example, some AAVs exhibit preferential tropism for muscle,(11) others target liver,(12) while others target the central nervous system (CNS) and peripheral nervous system (PNS) af…”
BackgroundInfluentialFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“Following AAV vector transduction, single stranded rAAV vector genomes are used as templates to form double-stranded (ds) linear rAAV monomers.(16) These go on to form ds circular monomers and DNA concatemers directed by host DNA polymerases and DNA repair pathways.”
MethodCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
AAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 7×
“To date, the genotoxicity associated with rAAV integrations in the Rian locus is derived from studies that treated mice as neonates at day 1 or 2 postpartum.(42,46,56,57,60) Increased rates of tumorigenesis, after treatment rAAV of juvenile/adult has been reported in WT mice treated with a LacZ vector but it is unclea…”
BackgroundMethodResultInfluentialMontini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571 · cited 1×
“Mouse models were also developed to test the genotoxicity of LV vectors used for liver-directed gene therapy, allowing the field to understand what vector features have the most profound impact on safety.(63,123,152) These studies indicated that the position and strength of the promoter within the vector backbone had…”
MethodSelf-citationGene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity
Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007280 · Cited by 562
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Self-citationThe clinical landscape for AAV gene therapies
Kuzmin, D. A., Shutova, M. V., Johnston, N. R., Smith, O. P., Fedorin, V. V., Kukushkin, Y. S., van der Loo, J. C. M., & Johnstone, E. C. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00017-7 · Cited by 503
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Self-citationLundstrom, K. (2018) · Diseases · doi:10.3390/diseases6020042 · Cited by 469
Integration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Self-citationMultiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908490 · Cited by 448
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Hacein-Bey-Abina, S., Pai, S.-Y., Gaspar, H. B., Armant, M., Berry, C. C., Blanche, S., Bleesing, J., Blondeau, J., de Boer, H., Buckland, K. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404588 · Cited by 412
Self-citationVector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403
Self-citationAAV serotype 2 vectors preferentially integrate into active genes in mice
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A. (2003) · Nature Genetics · doi:10.1038/ng1179 · Cited by 392
Self-citationModlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387
Nathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR)
Schmidt, M., Schwarzwaelder, K., Bartholomae, C., Zaoui, K., Ball, C., Pilz, I., Braun, S., Glimm, H., & von Kalle, C. (2007) · Nature Methods · doi:10.1038/nmeth1103 · Cited by 328
Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors
Zychlinski, D., Schambach, A., Modlich, U., Maetzig, T., Meyer, J., Grassman, E., Mishra, A., & Baum, C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.5 · Cited by 271
Adeno-associated virus vectors integrate at chromosome breakage sites
Miller, D. G., Petek, L. M., & Russell, D. W. (2004) · Nature Genetics · doi:10.1038/ng1380 · Cited by 266
George, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
Large‐scale molecular characterization of adeno‐associated virus vector integration in mouse liver
Nakai, H., Wu, X., Fuess, S., Storm, T. A., Munroe, D., Montini, E., Burgess, S. M., Grompe, M., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3606-3614.2005 · Cited by 190 · cited 1×
“Further studies that characterized the integration sites in more detail found that the majority of integration events were in intragenic locations, in transcriptionally active regions, near CpG islands, or near transcription start sites.(17,39,40) In addition, studies suggested that rAAV integration was dependent on d…”
BackgroundSelf-citationUncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo
Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.3 · Cited by 189
Self-citationGil-Farina, I., Fronza, R., Kaeppel, C., Lopez-Franco, E., Ferreira, V., D'Avola, D., Benito, A., Prieto, J., Petry, H., Gonzalez-Aseguinolaza, G., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.52 · Cited by 179 · cited 3×
“There are examples of estimates in large animal models and humans.(27,76,81,88,102) Other approaches are also possible.”
BackgroundViral Vectors for Gene Transfer
Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.58 · Cited by 146
Self-citationAAV vector-mediated in vivo reprogramming into pluripotency
Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05059-x · Cited by 64
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Meuse, L., Finegold, M., Grompe, M., & Kay, M. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00023-0 · Cited by 52 · cited 1×
“These go on to form ds circular monomers and DNA concatemers directed by host DNA polymerases and DNA repair pathways.(17,18) WT AAV can be maintained as an episome or integrate into the target cell genome mediated by Rep occurring preferentially at a locus on chromosome 19 in humans and also at other chromosome locat…”
BackgroundLiver gene therapy and hepatocellular carcinoma: A complex web
de Jong, Y. P., & Herzog, R. W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.009 · Cited by 29
Research works printed but not linked: 115
- Schmidt, 2008, Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942), J. Virol., 82, 8911, 10.1128/JVI.00672-08 · DOI
- Weinmann, 2017, Next-generation AAV vectors for clinical use: an ever-accelerating race, Virus Genes, 53, 707, 10.1007/s11262-017-1502-7 · DOI
- Berry, 2016, Cellular transduction mechanisms of adeno-associated viral vectors, Curr. Opin. Virol., 21, 54, 10.1016/j.coviro.2016.08.001 · DOI
- Pattali, 2019, AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy, Gene Ther., 26, 287, 10.1038/s41434-019-0085-4 · DOI
- Pei, 2020, Development of AAV variants with human hepatocyte tropism and neutralizing antibody escape capacity, Mol. Ther. Methods Clin. Dev., 18, 259, 10.1016/j.omtm.2020.06.003 · DOI
- Kantor, 2014, Methods for gene transfer to the central nervous system, Adv. Genet., 87, 125, 10.1016/B978-0-12-800149-3.00003-2 · DOI · Paper page
- Kotin, 1990, Site-specific integration by adeno-associated virus, Proc. Natl. Acad. Sci. U S A, 87, 2211, 10.1073/pnas.87.6.2211 · DOI · Paper page
- Samulski, 1991, Targeted integration of adeno-associated virus (AAV) into human chromosome 19, EMBO. J., 10, 3941, 10.1002/j.1460-2075.1991.tb04964.x · DOI · Paper page
- Hüser, 2010, Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome, PLoS. Pathog., 6, e1000985, 10.1371/journal.ppat.1000985 · DOI
- Nowrouzi, 2012, Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver, Mol. Ther., 20, 1177, 10.1038/mt.2012.47 · DOI
- Chandler, 2016, Genotoxicity in mice following AAV gene delivery: a safety concern for human gene therapy?, Mol. Ther., 24, 198, 10.1038/mt.2016.17 · DOI
- Chandler, 2017, Recombinant adeno-associated viral integration and genotoxicity: insights from animal models, Hum. Gene Ther., 28, 314, 10.1089/hum.2017.009 · DOI · Paper page
- Rutledge, 1997, Adeno-associated virus vector integration junctions, J. Virol., 71, 8429, 10.1128/jvi.71.11.8429-8436.1997 · DOI
- Yang, 1997, Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro, J. Virol., 71, 9231, 10.1128/jvi.71.12.9231-9247.1997 · DOI · Paper page
- Nakai, 1999, Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver, J. Virol., 73, 5438, 10.1128/JVI.73.7.5438-5447.1999 · DOI · Paper page
- Miller, 2005, Large-scale analysis of adeno-associated virus vector integration sites in normal human cells, J. Virol., 79, 11434, 10.1128/JVI.79.17.11434-11442.2005 · DOI · Paper page
- Donsante, 2001, Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors, Gene Ther., 8, 1343, 10.1038/sj.gt.3301541 · DOI · Paper page
- Sands, 1993, A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII, Proc. Natl. Acad. Sci. U S A, 90, 6567, 10.1073/pnas.90.14.6567 · DOI
- Daly, 2001, Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer, Gene Ther., 8, 1291, 10.1038/sj.gt.3301420 · DOI
- Daly, 1999, Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice, Hum. Gene Ther., 10, 85, 10.1089/10430349950019219 · DOI
- Bell, 2005, No evidence for tumorigenesis of AAV vectors in a large-scale study in mice, Mol. Ther., 12, 299, 10.1016/j.ymthe.2005.03.020 · DOI
- Bell, 2006, Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver, Mol. Ther., 14, 34, 10.1016/j.ymthe.2006.03.008 · DOI
- Zhong, 2013, Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction, Hum. Gene Ther., 24, 520, 10.1089/hum.2012.112 · DOI
- Reiss, 2011, Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2, Hum. Mutat., 32, 10, 10.1002/humu.21390 · DOI · Paper page
- Embury, 2008, Hepatitis Virus Protein X-Phenylalanine Hydroxylase fusion proteins identified in PKU mice treated with AAV-WPRE vectors, Gene Ther. Mol. Bio., 12, 69
- Li, 2011, Assessing the potential for AAV vector genotoxicity in a murine model, Blood, 117, 3311, 10.1182/blood-2010-08-302729 · DOI · Paper page
- Wang, 2012, Induction of hepatocellular carcinoma by in vivo gene targeting, Proc. Natl. Acad. Sci. U S A, 109, 11264, 10.1073/pnas.1117032109 · DOI
- Rosas, 2012, Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity, Mol. Ther., 20, 2098, 10.1038/mt.2012.197 · DOI
- Kao, 2013, Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo, Thromb. Haemost., 110, 244, 10.1160/TH13-02-0154 · DOI
- Walia, 2015, Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates, Mol. Ther., 23, 414, 10.1038/mt.2014.240 · DOI
- Kang, 2019, Pathogenesis of hepatic tumors following gene therapy in murine and canine models of glycogen storage disease, Mol. Ther. Methods Clin. Dev., 15, 383, 10.1016/j.omtm.2019.10.016 · DOI
- Dalwadi, 2021, Liver injury increases the incidence of HCC following AAV gene therapy in mice, Mol. Ther., 29, 680, 10.1016/j.ymthe.2020.10.018 · DOI
- Li, 2021, Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for Krabbe disease, Mol. Ther., 29, 691, 10.1016/j.ymthe.2020.12.031 · DOI
- Dupuy, 2009, A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice, Cancer Res., 69, 8150, 10.1158/0008-5472.CAN-09-1135 · DOI · Paper page
- Riordan, 2013, Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis, PLoS. Genet., 9, e1003441, 10.1371/journal.pgen.1003441 · DOI
- Ranzani, 2013, Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer, Nat. Methods, 10, 155, 10.1038/nmeth.2331 · DOI
- Hu, 2021, LncRNA MEG8 plays an oncogenic role in hepatocellular carcinoma progression through miR-367-3p/14-3-3ζ/TGFβR1 axis, Neoplasma, 68, 273, 10.4149/neo_2020_200730N785 · doi:10.4149/neo_2020_200730n785
- Cataldi, 2010, Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes, J. Virol., 84, 8673, 10.1128/JVI.00641-10 · DOI
- Knudson, 1971, Mutation and cancer: statistical study of retinoblastoma, Proc. Natl. Acad. Sci. U S A, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
- Colella, 2018, Emerging issues in AAV-mediated in vivo gene therapy, Mol. Ther. Methods Clin. Dev., 8, 87, 10.1016/j.omtm.2017.11.007 · DOI · Paper page
- Ferla, 2021, Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors, Mol. Ther. Methods Clin. Dev., 20, 247, 10.1016/j.omtm.2020.11.015 · DOI
- Li, 2012, Transcriptome comparison between fetal and adult mouse livers: implications for circadian clock mechanisms, PLoS One, 7, e31292, 10.1371/journal.pone.0031292 · DOI
- Kim, 2017, Points to consider in designing and conducting juvenile toxicology studies, Int. J. Toxicol., 36, 325, 10.1177/1091581817699975 · doi:10.1177/1091581817699975
- Gauttier, 2013, No tumour-initiating risk associated with scAAV transduction in newborn rat liver, Gene Ther., 20, 779, 10.1038/gt.2013.7 · DOI
- Schmidt, 1990, The cytomegalovirus enhancer: a pan-active control element in transgenic mice, Mol. Cell. Biol., 10, 4406
- Kay, 1992, Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo, Hum. Gene Ther., 3, 641, 10.1089/hum.1992.3.6-641 · DOI · Paper page
- Mattar, 2017, In utero transfer of adeno-associated viral vectors produces long-term factor IX levels in a cynomolgus macaque model, Mol. Ther., 25, 1843, 10.1016/j.ymthe.2017.04.003 · DOI
- Spronck, 2020, Assessment of vector integration of AAV5-hFIX in mice and non-human primates indicates No association with tumorigenic risk [Abstract], Res. Pract. Thromb. Haemost., 4
- Sullivan, 2021, Rare genomic integrations of AAV5-hFVIII-SQ occur without evidence of clonal activation or gene-specific targeting, Mol. Ther., 29, 425
- Mattar, 2011, Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques, Mol. Ther., 19, 1950, 10.1038/mt.2011.107 · DOI
- Niemeyer, 2009, Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy, Blood, 113, 797, 10.1182/blood-2008-10-181479 · DOI · Paper page
- Nguyen, 2021, A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells, Nat. Biotechnol., 39, 47, 10.1038/s41587-020-0741-7 · DOI · Paper page
- Batty, 2020, Long-term vector genome outcomes and immunogenicity of AAV FVIII gene transfer in the hemophilia A dog model [abstract], Res. Pract. Thromb. Haemost., 4
- Batty, 2020, Frequency, location and nature of AAV vector insertions after long-term follow up of FVIII transgene delivery in a Hemophilia A dog model [abstract], Res. Pract. Thromb. Haemost., 4
- Li, 2009, Multi-stage analysis of gene expression and transcription regulation in C57/B6 mouse liver development, Genomics, 93, 235, 10.1016/j.ygeno.2008.10.006 · DOI
- Sabatino, 2011, Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors, Mol. Ther., 19, 442, 10.1038/mt.2010.240 · DOI
- Venditti, 2021, Safety questions for AAV gene therapy, Nat. Biotechnol., 39, 24, 10.1038/s41587-020-00756-9 · DOI
- Arruda, 2004, Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1, Blood, 103, 85, 10.1182/blood-2003-05-1446 · DOI
- Nichols, 2015, Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs, Hum. Gene Ther. Clin. Dev., 26, 5, 10.1089/humc.2014.153 · DOI
- Dalwadi, 2021, AAV integration in human hepatocytes, Mol. Ther., 29, 2898, 10.1016/j.ymthe.2021.08.031 · DOI
- Nathwani, 2018, Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing "empty viral particles" on safety and efficacy of gene transfer, Blood, 132, 491, 10.1182/blood-2018-99-118334 · DOI
- George, 2021, Multiyear factor VIII expression after AAV gene transfer for hemophilia A, N. Engl. J. Med., 385, 1961, 10.1056/NEJMoa2104205 · DOI · Paper page
- Srivastava, 2017, AAV infection: protection from cancer, Hum. Gene Ther., 28, 323, 10.1089/hum.2016.147 · DOI
- Kaeppel, 2013, A largely random AAV integration profile after LPLD gene therapy, Nat. Med., 19, 889, 10.1038/nm.3230 · DOI · Paper page
- Pañeda, 2013, Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria, Hum. Gene Ther., 24, 1007, 10.1089/hum.2013.166 · DOI
- Schmidt, 2021, Liver safety case report from the phase 3 HOPE-B gene therapy trial in adults with hemophilia B [abstract], Res. Pract. Thromb. Haemost., 5
- Bushman, 2021, Challenges in estimating numbers of vectors integrated in gene-modified cells using DNA sequence information, Mol. Ther., 29, 3328, 10.1016/j.ymthe.2021.10.022 · doi:10.1016/j.ymthe.2021.10.022
- Sherman, 2017, INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes, Mol. Ther. Methods Clin. Dev., 4, 39, 10.1016/j.omtm.2016.11.002 · DOI
- Berry, 2017, INSPIIRED: quantification and visualization tools for analyzing integration site distributions, Mol. Ther. Methods Clin. Dev., 4, 17, 10.1016/j.omtm.2016.11.003 · DOI
- Locatelli, 2022, Betibeglogene Autotemcel gene therapy for non-β0/β0 genotype β-Thalassemia, N. Engl. J. Med., 386, 415, 10.1056/NEJMoa2113206 · DOI · Paper page
- Berry, 2012, Estimating abundances of retroviral insertion sites from DNA fragment length data, J. Bioinform., 28, 755
- Tai, 2018, Adeno-associated virus genome population sequencing achieves full vector genome resolution and reveals human-vector chimeras, Mol. Ther. Methods Clin. Dev., 9, 130, 10.1016/j.omtm.2018.02.002 · DOI · Paper page
- Zhang, 2021, Flies in the ointment: AAV vector preparations and tumor risk, Mol. Ther., 29, 2637, 10.1016/j.ymthe.2021.08.016 · DOI
- Dash, 2019, Differentiating between cancer and normal tissue samples using multi-hit combinations of genetic mutations, Sci. Rep., 9
- Guerin, 2020, A novel next-generation sequencing and analysis platform to assess the identity of recombinant adeno-associated viral preparations from viral DNA extracts, Hum. Gene Ther., 31, 664, 10.1089/hum.2019.277 · DOI
- Chao, 2006, Abundance-based similarity indices and their estimation when there are unseen species in samples, Biometrics, 62, 361, 10.1111/j.1541-0420.2005.00489.x · DOI · Paper page
- Cesana, 2021, Retrieval of vector integration sites from cell-free DNA, Nat. Med., 27, 1458, 10.1038/s41591-021-01389-4 · DOI
- Cesana, 2021, Liquid-biopsy-integration-site sequencing allows safety studies and longitudinal monitoring of vector integration sites in LV and AAV-based in-vivo GT applications, Mol. Ther., 29, 129
- Bijlani, 2022, The role of recombinant AAV in precise genome editing, Front. Genome Ed., 3, 799722, 10.3389/fgeed.2021.799722 · DOI
- Berry, 2006, Selection of target sites for mobile DNA integration in the human genome, PLoS Comput. Biol., 2, e157, 10.1371/journal.pcbi.0020157 · DOI · Paper page
- Bushman, 2020, Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones, Mol. Ther., 28, 352, 10.1016/j.ymthe.2019.12.009 · DOI
- Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
- Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1, Nat. Med., 12, 401, 10.1038/nm1393 · DOI · Paper page
- Cavazzana, 2019, Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges, Nat. Rev. Drug Discov., 18, 447, 10.1038/s41573-019-0020-9 · DOI · Paper page
- Deichmann, 2007, Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy, J. Clin. Invest., 117, 2225, 10.1172/JCI31659 · DOI · Paper page
- Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J. Clin. Invest., 118, 3143, 10.1172/JCI35798 · DOI · Paper page
- Stein, 2010, Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, Nat. Med., 16, 198, 10.1038/nm.2088 · DOI · Paper page
- Klein, 2003, Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice, Blood, 101, 2159, 10.1182/blood-2002-05-1423 · DOI
- Lo, 1999, Rapid clearance of fetal DNA from maternal plasma, Am. J. Hum. Genet., 64, 218, 10.1086/302205 · DOI · Paper page
- Otsu, 2000, Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy, Mol. Ther., 1, 145, 10.1006/mthe.1999.0020 · DOI
- Stein, 2013, From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease, Hum. Gene Ther. Clin. Dev., 24, 86, 10.1089/humc.2013.019 · DOI
- Strom, 2003, Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein, Gene Ther., 10, 803, 10.1038/sj.gt.3301950 · DOI
- Li, 2002, Murine leukemia induced by retroviral gene marking, Science, 296, 497, 10.1126/science.1068893 · DOI · Paper page
- Modlich, 2008, Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16, Leukemia, 22, 1519, 10.1038/leu.2008.118 · DOI
- Modlich, 2005, Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis, Blood, 105, 4235, 10.1182/blood-2004-11-4535 · DOI · Paper page
- Will, 2007, Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials, Mol. Ther., 15, 782, 10.1038/sj.mt.6300083 · DOI
- Modlich, 2006, Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity, Blood, 108, 2545, 10.1182/blood-2005-08-024976 · DOI · Paper page
- Cesana, 2012, Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations, J. Clin. Invest., 122, 1667, 10.1172/JCI62189 · DOI
- Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat. Biotechnol., 24, 687, 10.1038/nbt1216 · DOI · Paper page
- Schwarzer, 2021, Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning, Mol. Ther., 29, 3383, 10.1016/j.ymthe.2021.06.017 · DOI
- Aiuti, 2013, Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome, Science, 341, 1233151, 10.1126/science.1233151 · DOI · Paper page
- Biffi, 2013, Quantitative visualization of DNA G-quadruplex structures in human cells, Nat. Chem., 5, 182, 10.1038/nchem.1548 · DOI · Paper page
- Hacein-Bey Abina, 2015, Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome, JAMA, 313, 1550, 10.1001/jama.2015.3253 · DOI · Paper page
- Naldini, 2011, Ex vivo gene transfer and correction for cell-based therapies, Nat. Rev. Genet., 12, 301, 10.1038/nrg2985 · DOI · Paper page
- Kay, 1992, Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes, Proc. Natl. Acad. Sci. U S A, 89, 89, 10.1073/pnas.89.1.89 · DOI · Paper page
- Logan, 2017, Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome, Nat. Genet., 49, 1267, 10.1038/ng.3893 · DOI
- El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061 · DOI · Paper page
- Verdera, 2020, AAV vector immunogenicity in humans: a long journey to successful gene transfer, Mol. Ther., 28, 723, 10.1016/j.ymthe.2019.12.010 · DOI · Paper page
- Nault, 2015, Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas, Nat. Gen., 47, 1187, 10.1038/ng.3389 · DOI · Paper page
- La Bella, 2020, Adeno-associated virus in the liver: natural history and consequences in tumour development, Gut, 69, 737, 10.1136/gutjnl-2019-318281 · DOI
- Berns, 2015, Adeno-associated virus type 2 and hepatocellular carcinoma?, Hum. Gen. Ther., 26, 779, 10.1089/hum.2015.29014.kib · DOI
- Büning, 2015, Adeno-associated vector toxicity-to Be or not to Be?, Mol. Ther., 23, 1673, 10.1038/mt.2015.182 · DOI
- Russell, 2015, Adeno-associated virus finds its disease, Nat. Genet., 47, 1104, 10.1038/ng.3407 · DOI
- Assaf, 2018, Considerations for preclinical safety assessment of adeno-associated virus gene therapy products, Toxicol. Patho., 46, 1020, 10.1177/0192623318803867 · DOI
- Hüser, 2014, Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing, J. Virol., 88, 11253, 10.1128/JVI.01356-14 · DOI
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Self-citationGrasemann, H., & Ratjen, F. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2216474 · Cited by 334
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Manufacturing cell and gene therapies: challenges in clinical translation
Lee, N. K., & Chang, J. W. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0382 · Cited by 78
“Although the overall frequency is low, genomic integration is also possible for AAVs [26, 27].”
BackgroundGene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
“Integration in the murine genome at the Rian locus induces hepatocellular carcinoma (HCC) in mice [221,222].”
Background
Metadata
- Authors
- Sabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R., Eggan, K. C., Gao, G., Gil-Farina, I., Kay, M. A., McCarty, D. M., Montini, E., Ndu, A., & Yuan, J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 30
- Issue
- 8
- Pages
- 2646-2663
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W4281664094
- Cited by
- 212
- References
- 35
- FWCI
- 23.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.